JB Chemicals & Pharmaceuticals Ltd reported a 30 percent decline in consolidated net profit at Rs 101 crore for the fourth quarter of FY26, while the board recommended a final dividend of ₹9.30 per equity share (930 percent) for the financial year, as the company navigates post-acquisition integration under the Gujarat-based Torrent Group.
Revenue from operations fell five percent year-on-year to ₹904 crore during the quarter, impacted by one-off adjustments linked to integration activities, inventory rationalisation and alignment of business practices with the parent company. Net profit after tax stood at Rs 101 crore, while adjusted net profit after tax came in at Rs 150 crore, excluding non-cash ESOP expenses, exceptional items and other one-offs, the company stated.
The company said India business grew two percent year-on-year to ₹526 crore in Q4, supported by steady domestic demand. For FY26, India operations rose nine percent to ₹2,461 crore, with the biosimilars (BGx) segment growing 11 percent. According to IQVIA MAT March 2026 data, India business grew 11 percent, ahead of the industry’s 10 percent growth, while the chronic portfolio expanded 19 percent versus 14 percent industry growth. Secondary market growth of 11 percent reflected underlying demand strength across both the quarter and full year period.
Performance during the quarter was affected by one-offs, including distribution network optimisation as part of integration, discontinuation of low-margin trade generics, alignment of trade and sales policies with the parent entity, and timing impacts from revised cut-off policies during post-acquisition integration. International formulations revenue declined nine percent to ₹259 crore in Q4, while FY26 revenue rose two percent to ₹1,154 crore. The segment was impacted by inventory rationalisation, changes in credit practices following change of control, and shipment delays due to container constraints, particularly in the Middle East.
The CDMO business declined 22 percent in the quarter due to a high base in the previous year, while full-year revenue remained flat at ₹445 crore. The company said the performance was influenced by elevated prior-year levels and lower customer inventory holdings. The company noted that Q4 represents a transitional phase following change of control, with post-acquisition integration underway to align business policies and operating frameworks with the parent organisation. It added that these impacts are temporary and expects performance to improve progressively from April onwards, supported by synergy benefits and operational alignment.